Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (130)	6/18/2001 1:13:07 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1005

Tuck, don't know and haven't heard anything more about agix, except F144 selling has continued. It's no help that AGIX is the sort of situation where I confront my incompetence. A safe probucol ought to be successful, but not meeting endpoints is a stock killer. Worse, the endpoint dispute appears to be with the partner; and is anyone excited about a systemic restenosis treatment anyway? One who was patient with my questions simply said beware lack of specificity of anti-vcam in chronic indications. I'd say all of that so mucks up the post lock-up premise that agix might not longer qualify for BLUE. Wilder